Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of YH22189 vs Telmisartan/Amlodipine and Rosuvastatin in Healthy Volunteers
NCT02608242Phase 1Terminated
- Sponsor
- Yuhan
- Start
- Nov 2015
- Primary completion
- Jun 2016
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + amlodipine + rosuvastatin in hypertension (HTN) and hyperlipidemia (3 arms), sponsored by Yuhan. Primary endpoints: Maximum Plasma Concentration (Cmax) of Telmisartan, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUClast) of Telmisartan and 4 more. Started Nov 2015; status: terminated.
02
Drugs
telmisartan + amlodipine + rosuvastatin
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT02608242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608242.